Phage therapy: Difference between revisions
From IDWiki
(Created page with "== Background == * Bacteriophages can be used to treat extensively drug-resistant infections, mostly gram-negative bacilli or mycobacteria * Phages need to be trained for the specific bacterium and may be used synergistically with antibiotics == Access == * Process is in development, in Canada * A regulatory nightmare == Canadian Companies == * [https://cytophage.com/ Cytophage] (Winnipeg) * [http://www.phageluxagrihealth.com/en/ Phagelux] (China-based compa...") |
No edit summary |
||
| Line 9: | Line 9: | ||
* A regulatory nightmare |
* A regulatory nightmare |
||
== |
== Companies == |
||
* Canadian companies |
|||
* [https://cytophage.com/ Cytophage] (Winnipeg) |
** [https://cytophage.com/ Cytophage] (Winnipeg) |
||
* [http://www.phageluxagrihealth.com/en/ Phagelux] (China-based company with site in Montreal) |
** [http://www.phageluxagrihealth.com/en/ Phagelux] (China-based company with site in Montreal) |
||
* See also the [https://phage.directory/ Phage Directory] |
|||
== Further Reading == |
== Further Reading == |
||
Latest revision as of 22:36, 28 June 2022
Background
- Bacteriophages can be used to treat extensively drug-resistant infections, mostly gram-negative bacilli or mycobacteria
- Phages need to be trained for the specific bacterium and may be used synergistically with antibiotics
Access
- Process is in development, in Canada
- A regulatory nightmare
Companies
- Canadian companies
- See also the Phage Directory
Further Reading
- Biological foundations of successful bacteriophage therapy. EMBO Mol Med. 2022:e12435.
